Litigation Details for CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)
✉ Email this page to a colleague
CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-09-06 |
| Court | District Court, D. New Jersey | Date Terminated | 2019-09-05 |
| Cause | 15:1126 Patent Infringement | Assigned To | Susan Davis Wigenton |
| Jury Demand | None | Referred To | Leda D. Wettre |
| Parties | ALVOGEN PINE BROOK, LLC; CELGENE CORPORATION; HON. GARRETT E. BROWN, JR.; LOTUS PHARMACEUTICAL CO., LTD. | ||
| Patents | 6,045,501; 6,315,720; 6,561,977; 6,755,784; 7,189,740; 7,465,800; 7,765,106; 7,765,107; 7,855,217; 7,895,059; 7,968,569; 8,112,290; 8,315,886; 8,404,717; 8,457,988; 8,530,498; 8,589,182; 8,626,531; 8,645,160; 8,648,095; 8,731,963; 9,056,120; 9,101,621; 9,101,622 | ||
| Attorneys | AARON SCOTT ECKENTHAL; BRIAN JOHN FORSATZ; CHARLES MICHAEL LIZZA; DAVID LEIGH MOSES; FRANK CHARLES CALVOSA; GARRETT E. BROWN , JR.; SARAH ANN SULLIVAN; TEDD WILLIAM VAN BUSKIRK; WILLIAM C. BATON; WILLIAM L. MENTLIK | ||
| Firms | Jams; Lerner David Littenberg Krumholz and Mentlik LLP; Lerner, David, Littenberg, Krumholz & Mentlik, LLP; Quinn Emanuel Uquhart & Sullival LLP; Quinn Emanuel Urquhart & Sullivan LLC; Saul Ewing Arnstein & Lehr LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD.
Details for CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-09-06 | 1 | expiration of United States Patent Nos. 5,635,517 (“the ʼ517 patent”); 6,315,720 (“the ʼ720 … 35 PageID: 2 patent”); 6,561,977 (“the ʼ977 patent”); 6,755,784 (“the ʼ784 patent”); 7,189,740 (“the…“the ʼ740 patent”); 7,465,800 (“the ʼ800 patent”); 7,855,217 (“the ʼ217 patent”); 7,968,569 (“the ʼ569…ʼ569 patent”); 8,315,886 (“the ʼ886 patent”); 8,404,717 (“the ʼ717 patent”); 8,530,498 (“the ʼ498 patent…,531 (“the ʼ531 patent”); 8,648,095 (“the ʼ095 patent”); 9,056,120 (“the ʼ120 patent”); 9,101,621 (“the | External link to document | |
| 2019-01-30 | 101 | Covenant Not to Sue for Infringement of U.S. Patent No. 7,855,217 (Attachments: # 1 Certificate of Service… 5 September 2019 2:17-cv-06842 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2019-02-21 | 105 | BIFURCATION AND STAY WITH RESPECT TO U.S. PATENT NOS. 6,315,720, 6,561,977, 6,775,784, 8,315,886 AND 8,626,531… 5 September 2019 2:17-cv-06842 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
